TNDM Quote, Financials, Valuation and Earnings

Perspective Therapeutics, Inc. has a net margin of -8.49% compared to Tandem Diabetes Care, Inc.'s net margin of -12425.36%. Tandem Diabetes Care, Inc.'s return on equity of -110.24% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.

Tandem Diabetes Care, Inc. has a consensus price target of $22.52, signalling upside risk potential of 13.02%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 414.97%. Given that Perspective Therapeutics, Inc. has higher upside potential than Tandem Diabetes Care, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than Tandem Diabetes Care, Inc..

Tandem Diabetes Care, Inc. has a beta of 1.685, which suggesting that the stock is 68.536% more volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.

Tandem Diabetes Care, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tandem Diabetes Care, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.

Tandem Diabetes Care, Inc. quarterly revenues are $249.3M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. Tandem Diabetes Care, Inc.'s net income of -$21.2M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Tandem Diabetes Care, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tandem Diabetes Care, Inc. is 1.32x versus 162.05x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Integra LifeSciences Holdings Corp. has a net margin of -8.49% compared to Tandem Diabetes Care, Inc.'s net margin of -1.34%. Tandem Diabetes Care, Inc.'s return on equity of -110.24% beat Integra LifeSciences Holdings Corp.'s return on equity of -37.15%.

Tandem Diabetes Care, Inc. has a consensus price target of $22.52, signalling upside risk potential of 13.02%. On the other hand Integra LifeSciences Holdings Corp. has an analysts' consensus of $15.50 which suggests that it could grow by 14.9%. Given that Integra LifeSciences Holdings Corp. has higher upside potential than Tandem Diabetes Care, Inc., analysts believe Integra LifeSciences Holdings Corp. is more attractive than Tandem Diabetes Care, Inc..

Tandem Diabetes Care, Inc. has a beta of 1.685, which suggesting that the stock is 68.536% more volatile than S&P 500. In comparison Integra LifeSciences Holdings Corp. has a beta of 1.064, suggesting its more volatile than the S&P 500 by 6.408%.

Tandem Diabetes Care, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integra LifeSciences Holdings Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tandem Diabetes Care, Inc. pays -- of its earnings as a dividend. Integra LifeSciences Holdings Corp. pays out -- of its earnings as a dividend.

Tandem Diabetes Care, Inc. quarterly revenues are $249.3M, which are smaller than Integra LifeSciences Holdings Corp. quarterly revenues of $402.1M. Tandem Diabetes Care, Inc.'s net income of -$21.2M is lower than Integra LifeSciences Holdings Corp.'s net income of -$5.4M. Notably, Tandem Diabetes Care, Inc.'s price-to-earnings ratio is -- while Integra LifeSciences Holdings Corp.'s PE ratio is 70.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tandem Diabetes Care, Inc. is 1.32x versus 0.63x for Integra LifeSciences Holdings Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Insulet Corp. has a net margin of -8.49% compared to Tandem Diabetes Care, Inc.'s net margin of 12.4%. Tandem Diabetes Care, Inc.'s return on equity of -110.24% beat Insulet Corp.'s return on equity of 18.92%.

Tandem Diabetes Care, Inc. has a consensus price target of $22.52, signalling upside risk potential of 13.02%. On the other hand Insulet Corp. has an analysts' consensus of $378.21 which suggests that it could grow by 22.97%. Given that Insulet Corp. has higher upside potential than Tandem Diabetes Care, Inc., analysts believe Insulet Corp. is more attractive than Tandem Diabetes Care, Inc..

Tandem Diabetes Care, Inc. has a beta of 1.685, which suggesting that the stock is 68.536% more volatile than S&P 500. In comparison Insulet Corp. has a beta of 1.374, suggesting its more volatile than the S&P 500 by 37.428%.

Tandem Diabetes Care, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tandem Diabetes Care, Inc. pays -- of its earnings as a dividend. Insulet Corp. pays out -- of its earnings as a dividend.

Tandem Diabetes Care, Inc. quarterly revenues are $249.3M, which are smaller than Insulet Corp. quarterly revenues of $706.3M. Tandem Diabetes Care, Inc.'s net income of -$21.2M is lower than Insulet Corp.'s net income of $87.6M. Notably, Tandem Diabetes Care, Inc.'s price-to-earnings ratio is -- while Insulet Corp.'s PE ratio is 89.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tandem Diabetes Care, Inc. is 1.32x versus 8.83x for Insulet Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Teleflex, Inc. has a net margin of -8.49% compared to Tandem Diabetes Care, Inc.'s net margin of -44.78%. Tandem Diabetes Care, Inc.'s return on equity of -110.24% beat Teleflex, Inc.'s return on equity of -7.84%.

Tandem Diabetes Care, Inc. has a consensus price target of $22.52, signalling upside risk potential of 13.02%. On the other hand Teleflex, Inc. has an analysts' consensus of $124.14 which suggests that it could grow by 4.22%. Given that Tandem Diabetes Care, Inc. has higher upside potential than Teleflex, Inc., analysts believe Tandem Diabetes Care, Inc. is more attractive than Teleflex, Inc..

Tandem Diabetes Care, Inc. has a beta of 1.685, which suggesting that the stock is 68.536% more volatile than S&P 500. In comparison Teleflex, Inc. has a beta of 0.954, suggesting its less volatile than the S&P 500 by 4.59%.

Tandem Diabetes Care, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Teleflex, Inc. offers a yield of 1.14% to investors and pays a quarterly dividend of $0.34 per share. Tandem Diabetes Care, Inc. pays -- of its earnings as a dividend. Teleflex, Inc. pays out 91.92% of its earnings as a dividend. Teleflex, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Tandem Diabetes Care, Inc. quarterly revenues are $249.3M, which are smaller than Teleflex, Inc. quarterly revenues of $913M. Tandem Diabetes Care, Inc.'s net income of -$21.2M is higher than Teleflex, Inc.'s net income of -$408.9M. Notably, Tandem Diabetes Care, Inc.'s price-to-earnings ratio is -- while Teleflex, Inc.'s PE ratio is 25.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tandem Diabetes Care, Inc. is 1.32x versus 1.69x for Teleflex, Inc.. Usually stocks with elevated PS ratios are considered overvalued.